Arena Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will present at the upcoming investor conferences:

• Credit Suisse 28th Annual Healthcare Conference – Presenting on Tuesday, November 12, at 10:00 AM ET (8:00 AM MT)
• Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day – Presenting on Monday, November 18, at 1:45 PM ET

A live audio webcast of each presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of each presentation will be available for 30 days following the event.

About Arena Pharmaceuticals
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential utility in a broad range of immune-mediated inflammatory conditions, is being evaluated in later-stage clinical programs in inflammatory bowel disease (IBD), a Phase 2 program in atopic dermatitis (AD), as well as for other potential indications. Arena is also evaluating olorinab (APD371) in a Phase 2 program for gastrointestinal pain. Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure.

Arena has additional license agreements and partnerships, including with United Therapeutics (ralinepag in a Phase 3 program for pulmonary arterial hypertension), Everest Medicines Limited (etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), Outpost Medicine, LLC (undisclosed target – Phase 1), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ^® – marketed product).

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming conferences and Arena's drive, assets, programs, licenses, and partnerships. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Corporate Contact:                                      
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer                                  
[email protected]
858.210.3636

Media Contact:
Matt Middleman, MD
LifeSci Public Relations
[email protected]
646.627.8384

SOURCE Arena Pharmaceuticals, Inc.